May 31, 2013
/PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the underwriters of its previously announced public offering of common stock, which was completed on
May 14, 2013
, have exercised their option to purchase an additional 617,869 shares of Isis' common stock. The closing of the sale of the additional shares is expected to take place on
June 4, 2013
, subject to customary closing conditions.
Including the 9,000,000 shares of common stock previously sold, the aggregate gross proceeds to Isis from this offering is expected to be approximately
, before deducting the underwriting discount and other estimated offering expenses payable by Isis. Isis anticipates using the net proceeds from the offering to increase its drug development activities, develop select drugs in it pipeline to later stages of development prior to partnering, and for general corporate and working capital purposes.
Goldman, Sachs & Co. and J.P. Morgan Securities LLC acted as joint book-running managers in the offering. Stifel acted as lead manager. BMO Capital Markets, Cowen and Company, LLC and Needham & Company acted as co-managers.
The securities described were offered by Isis pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the "SEC"), which became effective on
, 2013. A copy of the prospectus supplement and the accompanying prospectus relating to these securities may be obtained by sending a request to Goldman, Sachs & Co. (Attn: Prospectus Department, 200 West Street,
New York, New York
10282, Fax: 212-902-9316 or Email at
or by calling 1-866-471-2526) or J.P. Morgan Securities LLC (c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
11717 or by calling 866-803-9204). Electronic copies of the prospectus supplements may be obtained by visiting EDGAR on the SEC's website at
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.